Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FEM Urovital is a non-hormonal dietary supplement formulated to support women's urinary health, bladder control, and overall urinary well-being. Developed under the FEM By UPSA brand, which combines the women's health research of Sérélys Pharma with the pharmaceutical heritage of UPSA, the product is designed to address overactive bladder-type symptoms such as urgency, frequency, and occasional leakage. Its formulation features UriCytonin (also known as Pure CyTonin), a patented, purified cytoplasmic pollen extract, combined with pumpkin seed extract and vitamin E. The supplement works naturally to support pelvic floor muscle function and strengthen bladder tone without hormonal activity. It is administered as an oral capsule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FEM Urovital.